Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes: 2014-2025

Historic Change in Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Sep 2025 value amounting to -$12.5 million.

  • Ani Pharmaceuticals' Change in Taxes fell 287.64% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year increase of 53.01%. This contributed to the annual value of -$1.4 million for FY2024, which is 111.80% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Taxes of -$12.5 million as of Q3 2025, which was down 15.18% from -$10.9 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Taxes ranged from a high of $12.9 million in Q4 2024 and a low of -$14.3 million during Q2 2024.
  • Over the past 3 years, Ani Pharmaceuticals' median Change in Taxes value was $92,000 (recorded in 2023), while the average stood at -$493,364.
  • In the last 5 years, Ani Pharmaceuticals' Change in Taxes skyrocketed by 15,538.78% in 2023 and then slumped by 3,942.21% in 2024.
  • Ani Pharmaceuticals' Change in Taxes (Quarterly) stood at -$637,000 in 2021, then soared by 92.31% to -$49,000 in 2022, then skyrocketed by 15,538.78% to $7.6 million in 2023, then spiked by 69.90% to $12.9 million in 2024, then tumbled by 287.64% to -$12.5 million in 2025.
  • Its Change in Taxes stands at -$12.5 million for Q3 2025, versus -$10.9 million for Q2 2025 and $7.4 million for Q1 2025.